Haemonetics Corporation has completed its acquisition of OpSens, the company announced in a press release today. Haemonetics acquired all outstanding shares of OpSens for CAD$2.90 per share in the all-cash transaction, representing a fully diluted equity value of approximately US$255 million at the current exchange rate. “Expanding our hospital portfolio with OpSens’ products creates exciting […]…
